Generic Prepopik Availability

Prepopik is a brand name of citric acid/magnesium oxide/sodium picosulfate, approved by the FDA in the following formulation(s):

PREPOPIK (citric acid; magnesium oxide; sodium picosulfate - for solution;oral)

  • Manufacturer: FERRING PHARMS AS
    Approval date: July 16, 2012
    Strength(s): 12GM/PACKET;3.5GM/PACKET;10MG/PACKET [RLD]

Has a generic version of Prepopik been approved?

No. There is currently no therapeutically equivalent version of Prepopik available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prepopik. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof
    Patent 8,450,338
    Issued: May 28, 2013
    Assignee(s): Ferring International Center S.A.
    Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
    Patent expiration dates:
    • October 10, 2028
      ✓ 
      Drug product
  • Granular compositions of magnesium oxide and citric acid and uses thereof
    Patent 8,481,083
    Issued: July 9, 2013
    Assignee(s): Ferring International Center S.A.
    Compositions are provided that are useful for the preparation of a medicament. The compositions comprise granules having a layer of sodium picosulphate coated on potassium bicarbonate. Additional granules having a layer of magnesium oxide coated on a core of citric acid are also provided. The two types of granules may be combined to obtain mixtures (preferably homogeneous or substantially homogeneous mixtures) of the two types of granules, which are useful, e.g., as pharmaceutical compositions.
    Patent expiration dates:
    • October 10, 2028
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 16, 2015 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)